In parallel, phase-3 programs for daprodustat (ASCEND trials) demonstrated noninferiority vs. epoetin for Hb response with broadly similar adverse-event rates, supporting on-label use in dialysis and non-dialysis CKD [109]. Here, GSTM1 is linked to chronic kidney disease.